With the first biosimilar version of a monoclonal antibody now under regulatory review in the European Union, which R&D strategies are innovators relying on to counteract competition?
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Mullard, A. Can next-generation antibodies offset biosimilar competition?. Nat Rev Drug Discov 11, 426–428 (2012). https://doi.org/10.1038/nrd3749
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3749
This article is cited by
-
Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects
European Journal of Drug Metabolism and Pharmacokinetics (2022)
-
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
Globalization and Health (2019)
-
Multi-parametric analysis reveals enhanced G2-phase arrest of an optimized anti-HER2 antibody to inhibit breast cancer
Biotechnology Letters (2017)
-
Innovation in biologic new molecular entities: 1986–2014
Nature Reviews Drug Discovery (2015)
-
Etanercept biosimilars
Rheumatology International (2015)
